GENE ONLINE|News &
Big Pharma and Non-Profits Join NIH, FDA in New Rare Diseases Drive
The US National Institutes of Health (NIH) and FDA have joined forces with 10 pharmas and five non-profits to boost the number of approved gene therapies for rare diseases.
The new partnership, called the Bespoke Gene Therapy Consortium (BGTC), will be part of the NIH Accelerating Medicines Program (AMP) and managed by the Foundation for the National Institutes of Health (FNIH). The NIH and private partners will contribute around $76 million in funding for the program over a five-year period. The participating NIH institutes and centers are expected to chip in over half the funds, at $39.5 million.
“Most rare diseases are caused by a defect in a single gene that could potentially be targeted with a customized or ‘bespoke’ therapy that corrects or replaces the defective gene,” said NIH Director Francis S. Collins, M.D., Ph.D.
The new partnership, called the Bespoke Gene Therapy Consortium (BGTC), will be part of the NIH Accelerating Medicines Program (AMP) and managed by the Foundation for the National Institutes of Health (FNIH). The NIH and private partners will contribute around $76 million in funding for the program over a five-year period. The participating NIH institutes and centers are expected to chip in over half the funds, at $39.5 million.
“Most rare diseases are caused by a defect in a single gene that could potentially be targeted with a customized or ‘bespoke’ therapy that corrects or replaces the defective gene,” said NIH Director Francis S. Collins, M.D., Ph.D.
GO Prime with only $1.49 now
LATEST
Psychedelics Inching Forward – Psilocybin Therapy Shows Sustained Benefits for Treatment-Resistant Depression
2025-03-24
Healthcare Through the Eyes of AI: Coding the Future of Medicine Through Digital Acceleration
2025-03-21
European Pharmaceutical Review Highlights RNA Therapeutics and Process Analytical Technology in 2025 Issue 1
2025-03-21
